Skip to Content
Merck
  • [Role of NO/cGMP signaling cascade in the development of opium dependency].

[Role of NO/cGMP signaling cascade in the development of opium dependency].

Eksperimental'naia i klinicheskaia farmakologiia (2013-06-19)
D I Peregud, A A Iakovleva, M Iu Stepanichev, L F Panchenko, N V Guliaeva
ABSTRACT

This study was aimed at evaluating the role of nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) cascade in mechanisms of morphine dependency formation. Morphine was introduced by intraperitoneal (i.p.) injections in rats twice per day over six days in doses increasing from 10 to 100 mg/kg, For evaluating the role of NO/cGMP cascade, NO synthase inhibitor L-N(G)-Nitroarginine methyl ester (L-NAME) was introduced (10 mg/kg, i.p.) 1 h prior to every injection of morphine. The L-NAME introduction led to enhancement of spontaneous withdrawal syndrome manifestations, which was accompanied by more pronounced decrease in the cGMP levels in midbrain and striatum. It is suggested that the region specific decrease in NO/cGMP cascade signaling activity in the brain can be among mechanisms determining the development of opium dependency.

MATERIALS
Product Number
Brand
Product Description

Supelco
Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Guanosine 3′,5′-cyclic monophosphate, ≥98% (HPLC), powder
Sigma-Aldrich
Nω-Nitro-L-arginine methyl ester hydrochloride, ≥97% (TLC), powder
Supelco
Morphine sulfate salt pentahydrate, analytical standard
Sigma-Aldrich
Morphine sulfate salt pentahydrate
Supelco
Morphine sulfate salt solution, 1.0 mg/mL in methanol, drug standard